Author/Authors :
Lotfali, Ensieh Department of Medical Parasitology and Mycology - School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran , Ghasemi, Reza , School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran , Mardani, Masoud Shahid Beheshti University of Medial Sciences, Tehran , Fattahi, Azam Tehran University of Medical Sciences, Tehran , Rezaei, Kamran School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran , Toreyhi, Hossein School of Medicine - Shahid Beheshti University of Medical Sciences, Tehran , Abolghasemi, Sara Shahid Beheshti University of Medial Sciences, Tehran
Abstract :
Since late 2019, when novel coronavirus pneumonia emerged in China and spread worldwide, there has been a need for data concerning the clinical characteristics of infected immunocompromised patients. It has been reported that a significant mortality rate occurs in individuals with underlying comorbidities such as hematologic malignancies. Therefore, it is vital to illustrate the clinical manifestations and outcomes of COVID-19 in these vulnerable patients and identify safe therapeutic strategies. This study reviewed the clinical course, laboratory findings, and risk factors associated with hematologic malignant patients with COVID-19 along with the management and therapeutic regimens.
Keywords :
Coronavirus , COVID-19 , SARS-CoV-2 , Severe Acute Respiratory Syndrome Coronavirus 2 , Hematological Malignant Patients
